ReviewJournal of ovarian research2022
Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
Review in Journal of ovarian research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis.BMC women's health · 2024Pooled it
- Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Pooled it
- Mechanistic Insights intoInternational journal of molecular sciences · 2026Article
- Development and validation of a miRNA-based prognostic model for high-grade serous ovarian cancer: a retrospective cohort study.Lancet regional health. Americas · 2026Article
- Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer.Journal of gynecologic oncology · 2026Article
- CX3CR1-Dependent Macrophages Drive Ovarian Cancer Progression Through MMP-2 and TGF-β Production.Cancers · 2026Article
- Prevalence of Homologous Recombination Deficiency and Treatment Patterns in Patients with Newly Diagnosed Advanced Ovarian Cancer in Bulgaria: A Real-World Cohort Study (VALIDATE).Medicina (Kaunas, Lithuania) · 2026Observational
- A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy.Journal of nanobiotechnology · 2026Article
- Nanoparticle based siRNA therapeutics for ovarian cancer overcoming drug resistance and future directions.Discover nano · 2026Review
- Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching.Protein & cell · 2026Article
- Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance.Advanced biology · 2026Article
- Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.Journal of clinical medicine · 2026Article
- Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.Journal for immunotherapy of cancer · 2026Review
- Development and Validation of a Multi-Omics Model Integrating US-Derived and WSI-Based Features to Predict Lymph Node Metastasis in Ovarian Cancer: A Multi-Center Retrospective Study.International journal of women's health · 2026Article
- Apoptotic effect of linifanib on human ovarian cancer OVCAR3 cell line.Research in pharmaceutical sciences · 2025Article
- KLF5-regulated ZDHHC8 reduces chemosensitivity in high-grade serous ovarian cancer through β-catenin signaling.Scientific reports · 2025Article
- Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis.Journal of ovarian research · 2025Article
- Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
- Genomic instability andFrontiers in oncology · 2025Article
- Disease-free survival of 15 years after primary surgery in a patient with advanced high-grade serous ovarian cancer: a case report and literature review.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer among women worldwide, with the 5-year survival rate ranging between 30 and 40%. Due to the asymptomatic nature of the condition, it is more likely to be diagnosed at an advanced stage, requiring an aggressive therapeutic approach. Cytoreductive surgery (CRS) along with systemic chemotherapy with paclitaxel and carboplatin has been the mainstay of the treatment in the frontline management of EOC. In recent years, neo-adjuvant chemotherapy, followed by interval CRS has become an important strategy for the management of advanced EOC. Due to the high rate of recurrence, the oncology community has begun to shift its focus to molecular-targeted agents and maintenance therapy in the frontline settings. The rationale for maintenance therapy is to delay the progression or relapse of the disease, as long as possible after first-line treatment, irrespective of the amount of residual disease. Tumours with homologous recombination deficiency (HRD) including BReast CAncer gene (BRCA) mutations are found to be sensitive to polyadenosine diphosphate-ribose polymerase (PARP) inhibitors and understanding of HRD status has become important in the frontline setting. PARP inhibitors are reported to provide a significant improvement in progression-free survival and have an acceptable safety profile. PARP inhibitors have also been found to act regardless of BRCA status. Recently, PARP inhibitors as maintenance therapy in the frontline settings showed encouraging results in EOC; however, the results from further trials and survival data from ongoing trials are awaited for understanding the role of this pathway in treatment of EOC. This review discusses an overview of maintenance strategies in newly diagnosed EOC along with considerations for maintenance therapy in EOC with a focus on PARP inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.